Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  Bioscience Valuation's comprehensive assessments of in-licensing candidates provide us with a thorough understanding of the opportunity, both from a scientific and business perspective.

Dr. Philipp R. Hoffmann, Senior Director Business Development & Licensing Europe, Daiichi Sankyo

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model


Bioscience Valuation's R&D Risk Model
Customers may license Bioscience Valuation's programs for their own use. Bioscience Valuation's R&D Risk Model enables our clients to fine-tune the probability of success for each development phase by considering:
  • therapeutic area or specific indication,
  • mode of action,
  • molecule type,
  • degree of innovation,
  • route of administration.

The model suggests particular success probabilities based on benchmark studies; however, the user can adjust individual probabilities to adapt the model to his specific needs. Furthermore, if combined with cost estimates, the model calculates the 'expected value of perfect information' that can aid investment decisions.

Please contact us for receiving further information, or to order the model.